Drug Trial Radar · NCT00005970
Doxorubicin Hydrochloride, Cyclophosphamide, and Pacltaxel With or Without Trastuzumab in Treating Women With HER2-Positive Node-Positive or High-Risk Node-Negative Breast Cancer
Last checked: Nov 19, 2026Latest source record: Aug 14, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
3,436
Actual
Start
May 19, 2000
Primary completion
Apr 25, 2005
Study completion Jan 27, 2010
Sponsor
- Lead sponsor
- National Cancer Institute (NCI)NIH
- Sponsor type
- NIH
- Collaborators
- Cancer and Leukemia Group B; Eastern Cooperative Oncology Group; Canadian Cancer Trials Group; SWOG Cancer Research Network
- First posted
- Jan 27, 2003
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This randomized phase III trial studies doxorubicin hydrochloride, cyclophosphamide, paclitaxel, and trastuzumab to see how well they work compared to combination chemotherapy alone in treating women with breast cancer that is human epidermal growth factor receptor 2 (HER2)-positive and has spread to the lymph nodes or high-risk and has not spread to the lymph nodes. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Monoclonal antibodies such as trastuzumab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. It is not yet known whether combination chemotherapy is more effective with or without trastuzumab in treating breast cancer.
Conditions
- Breast Adenocarcinoma
- HER2 Positive Breast Carcinoma
- Stage IA Breast Cancer AJCC v7
- Stage IB Breast Cancer AJCC v7
- Stage IIA Breast Cancer AJCC v6 and v7
- Stage IIB Breast Cancer AJCC v6 and v7
- Stage IIIA Breast Cancer AJCC v7
Interventions
Aromatase Inhibition TherapyDrug
Given orally
CyclophosphamideDrug
Given IV
Doxorubicin HydrochlorideDrug
Given IV
Laboratory Biomarker AnalysisOther
Correlative studies
PaclitaxelDrug
Given IV
Tamoxifen CitrateDrug
Given orally
TrastuzumabBiological
Given IV
Primary outcomes
What the sponsor says the trial is designed to measure.
- Duration of DFSTime frame: Time from registration to first adverse event, assessed up to 15 years
Locations
157 sites in 4 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham Cancer Center
Birmingham, Alabama
Western Regional CCOP
Phoenix, Arizona
Mayo Clinic in Arizona
Scottsdale, Arizona
Banner University Medical Center - Tucson
Tucson, Arizona
University of Arkansas for Medical Sciences
Little Rock, Arkansas
Community Cancer Institute
Clovis, California
City of Hope Comprehensive Cancer Center
Duarte, California
Washington Hospital
Fremont, California
Glendale Memorial Hospital and Health Center
Glendale, California
USC / Norris Comprehensive Cancer Center
Los Angeles, California
Memorial Medical Center
Modesto, California
Community Hospital of Monterey Peninsula
Monterey, California
UC Irvine Health/Chao Family Comprehensive Cancer Center
Orange, California
Stanford Cancer Institute Palo Alto
Palo Alto, California
University of California Davis Comprehensive Cancer Center
Sacramento, California
Salinas Valley Memorial
Salinas, California
University of California San Diego
San Diego, California
Naval Medical Center -San Diego
San Diego, California
UCSF Medical Center-Mount Zion
San Francisco, California
The Angeles Clinic and Research Institute - Santa Monica Office
Santa Monica, California
Santa Rosa Memorial Hospital
Santa Rosa, California
University of Colorado Hospital
Aurora, Colorado
MedStar Georgetown University Hospital
Washington D.C., District of Columbia
Mayo Clinic in Florida
Jacksonville, Florida
AdventHealth Orlando
Orlando, Florida
Moffitt Cancer Center
Tampa, Florida
Emory University Hospital/Winship Cancer Institute
Atlanta, Georgia
Atlanta Regional CCOP
Atlanta, Georgia
Northeast Georgia Medical Center-Gainesville
Gainesville, Georgia
Memorial Health University Medical Center
Savannah, Georgia
University of Hawaii Cancer Center
Honolulu, Hawaii
Northwestern University
Chicago, Illinois
Rush University Medical Center
Chicago, Illinois
University of Illinois
Chicago, Illinois
University of Chicago Comprehensive Cancer Center
Chicago, Illinois
Heartland Cancer Research NCORP
Decatur, Illinois
Loyola University Medical Center
Maywood, Illinois
Carle Cancer Center
Urbana, Illinois
Indiana University/Melvin and Bren Simon Cancer Center
Indianapolis, Indiana
Northern Indiana Cancer Research Consortium
South Bend, Indiana
Showing 40 of 157 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.